Camurus AB
STO:CAMX
Net Margin
Camurus AB
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| SE |
|
Camurus AB
STO:CAMX
|
32.7B SEK |
23%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
694B USD |
24%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
365.2B USD |
16%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
199.2B CHF |
20%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
177.4B CHF |
23%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
157.8B GBP |
13%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
200.5B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
-126%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
114.1B EUR |
13%
|
Camurus AB
Glance View
Camurus AB is a Swedish pharmaceutical company that stands out in the industry with its innovative approach to treating chronic and rare diseases. Rooted in its proprietary FluidCrystal® injection depot technology, Camurus integrates this platform into the development of long-acting medications that aim to improve patient compliance and outcomes. This lipid-based system allows for the extended release of active substances, providing sustained therapeutic effects from just a single dose. Founded in 1991, the company has strategically focused its efforts on areas often underserved by traditional pharmaceutical giants, such as addiction, pain management, and endocrine disorders. By concentrating on these specific therapeutic areas, Camurus not only addresses significant health challenges but also carves out a niche with limited competition, potentially leading to substantial revenue streams. The company generates its income predominantly through product sales and strategic partnerships. One of its flagship products is Buvidal®, a long-acting medication for the treatment of opioid dependence, which has made significant inroads across Europe and Australia. The sustained revenue from Buvidal® highlights the company's adeptness at capitalizing on its technology to create tangible healthcare solutions. Additionally, Camurus engages in licensing agreements and collaborations with international pharmaceutical firms, expanding its market reach and leveraging its technology across a broader canvas. By investing heavily in research and development, Camurus ensures its pipeline continues to be robust, with new products consistently in various stages of clinical trials, thereby securing its financial performance and position in the pharmaceutical industry.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Camurus AB's most recent financial statements, the company has Net Margin of 22.9%.
You don't have any saved screeners yet